Top Industry Leaders in the Cardiac Resynchronization Therapy Market
Latest Cardiac Resynchronization Therapy Companies Update
October 2021: Abbott announced the launch of its new implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for abnormal heart rhythms and heart failure. CRT-Ds are used to prevent sudden death similar to traditional ICDs, but in addition act to restore the heart’s natural pattern of beating in patients with reduced cardiac function and progressive heart failure despite optimal medical therapy. The devices offer new opportunities for patient engagement and remote monitoring through smartphone connectivity and connected applications. Additional benefits include a patient preferred design, improved battery longevity and MRI compatibility. The new system pairs with Abbott's secure remote monitoring app which is smartphone compatible.
March 2021: The Optimizer Smart System, created by Impulse Dynamics, monitors heart activity and delivers non-excitatory electrical signals to the right ventricle. The maker claims it provides patients with a higher quality of life and functional status, compared with those who only took medications. Unlike a pacemaker, which regulates the rhythm of the heart, the OSS strengthens the muscle contractions. The Food and Drug Administration approved a breakthrough medical device last week for patients suffering from chronic, hard-to-treat heart failure. The Optimizer Smart System, created by Impulse Dynamics, monitors heart activity and delivers non-excitatory electrical signals to the right ventricle. These are patients who have a marked limitation of physical activity and who remain symptomatic despite receiving optimal medical therapy.
List of Cardiac Resynchronization Therapy Key companies in the market
- Medtronic
- Abbott
- BIOTRONIK, Inc.
- Boston Scientific Corporation
- Lepu Medical Technology Co., Ltd.
- Medico S.p.A.
- MicroPort Scientific Corporation
- Shree Pacetronix Ltd